Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Yumanity Therapeutics Completes Its Previously Announced Sale Of All Of Its Rights, Title And Interest In And To Clinical-stage Product Candidate YTX-7739 As Well As It's Unpartnered Pre-clinical And Discovery-stage Product Candidates And Related Intellectual Property Rights To Janssen Pharmaceutica Nv For A Purchase Price Of $26M In Cash

Author: Benzinga Newsdesk | December 15, 2022 08:00am

Posted In: YMTX